← Human Trials & Peer-Reviewed Studies
Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal Osteoporosis
Plain-language guide to PMID 35033435 (2022): open-label and placebo-controlled clinical trial study of Abaloparatide and Teriparatide.
Key Facts
- PMID
- 35033435
- Journal
- Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
- Year
- 2022
- Study type
- Clinical Trial
- Authors
- Winzenrieth R et al. (6 authors)
- DOI
- 10.1016/j.jocd.2021.11.007
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at Abaloparatide and Teriparatide.
The current analyses from this subgroup describe 2D- and 3D-DXA data for hip subregions.
Areal BMD of the femoral neck, trochanter, and femoral shaft was determined using standard 2D-DXA and 3D-SHAPER software to retrospectively evaluate changes from baseline in volumetric parameters of these 3 hip subregions, including trabecular and cortical segmentation.
Who Took Part
PubMed tags the participants as women only.
How the Study Was Run
The researchers set it up as an open-label and placebo-controlled study.
Nothing was hidden in this open-label Abaloparatide study: the participants and staff both knew the treatment.
The comparison arm used a placebo, so changes seen with Abaloparatide could be set against what happens without it.
What Was Measured
Areal BMD of the femoral neck, trochanter, and femoral shaft was determined using standard 2D-DXA and 3D-SHAPER software to retrospectively evaluate changes from baseline in volumetric parameters of these 3 hip subregions, including trabecular and cortical segmentation.
Changes in biomechanical parameters cross-sectional moment of inertia (CSMI), section modulus (Z), and buckling ratio were also evaluated.
PubMed files the paper under topics including Absorptiometry, Photon, Bone Density, Cross-Sectional Studies, Osteoporosis, Postmenopausal, Parathyroid Hormone-Related Protein and Teriparatide.
Author keywords: 3D modeling, Abaloparatide, Dual X-ray absorptiometry, cortical volumetric BMD and strength indices.
What This Means in Plain Language
The paper is an open-label and placebo-controlled study of Abaloparatide and Teriparatide.
The publication is from 2022 (Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry), a journal based in United States.
More context: the Abaloparatide compound page and the Teriparatide compound page, all human trials.
Our Notes on the Compounds
Abaloparatide: A synthetic parathyroid hormone-related peptide (PTHrP) analog used as a bone-building (anabolic) osteoporosis medicine.
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.